fda green list import alert 66-80 glp-1 Issues on GLP-1s Following Launch of “Green List” Getting the Green Light: FDA's
Description
But users found that it also increased hair growth, which was first considered an unsightly side effect
Furthermore, the study carefully selects trials that focus exclusively on the GI adverse effects of GLP-1 RA in RCTs involving adults with overweight or obesity
The takeaway isnt that combination therapy is the answer
Semaglutide is not for use in people with type 1 diabetes
All data were reproduced in 3 - 5 independent experiments
(Brief Background) Let me give you quick background for context
